(Reuters) – Valneva’s COVID-19 vaccine has received marketing authorisation from the European Commission for use as a primary vaccination in people from 18 to 50 years of age, the company said on Friday.
(Reporting by Valentine Baldassari; Editing by Jan Harvey)
